PEABODY, Mass., June 3, 2021  -- Privo Technologies, Inc. (“Privo”), a biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough... read more

Privo Technologies has been awarded ~$2 million in funding from the FDA through its Office of Orphan Product Development (OOPD)... read more

Privo Technologies is pleased to announce that the company has won the 2016 National Tibbetts award for outstanding contributions to... read more

Privo Technologies Inc., a pioneering biopharmaceutical company known for its innovative approach to drug delivery and cancer treatment, is proud... read more

Peabody, MA-- Privo Technologies, Inc. (“Privo”), a clinical-stage biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer,... read more

Watch Dr. Goldberg's presentation below regarding localized treatment of cancers in a more safe and effective way and the positive... read more

Key Highlights: 92% complete response (CR) rate: Eleven of twelve evaluable patients achieved a centrally confirmed pathologic CR following a... read more

Privo Technologies, Inc. is pleased to announce that it has received IRB approval for its CLN-004 study from WCG... read more

Privo Technologies received Orphan Designation for anatomically accessible oral cancers. Receipt of this designation entitles Privo’s current and future oral... read more

Privo Technologies is proud to serve as both an exhibitor and selected speaker at the RESI conference in Boston and... read more